Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

CytomX Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

CytomX Therapeutics'in gelir ve kazançlarının sırasıyla 15.2% ve 27.9% yıllık düşüş göstermesi beklenirken, EPS'nin 28.8% azalması beklenmektedir.

Anahtar bilgiler

-27.9%

Kazanç büyüme oranı

-28.8%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.6%
Gelir büyüme oranı	-15.2%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	13 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

May 02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 29

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Feb 13

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10

CytomX Therapeutics to cut workforce by about 40%

Jul 13

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Jul 06

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:CTMX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	67	-57	-37	N/A	2
12/31/2025	73	-59	-40	-66	5
12/31/2024	100	-27	-44	-65	6
6/30/2024	120	11	-86	-86	N/A
3/31/2024	119	17	-92	-91	N/A
12/31/2023	101	-1	-57	-56	N/A
9/30/2023	95	-10	-36	-35	N/A
6/30/2023	79	-42	-52	-51	N/A
3/31/2023	68	-71	-61	-60	N/A
12/31/2022	53	-99	-113	-111	N/A
9/30/2022	21	-149	-142	-141	N/A
6/30/2022	27	-143	-138	-136	N/A
3/31/2022	30	-132	-132	-130	N/A
12/31/2021	37	-116	-121	-119	N/A
9/30/2021	66	-72	-107	-105	N/A
6/30/2021	66	-64	-103	-100	N/A
3/31/2021	67	-61	23	25	N/A
12/31/2020	68	-65	3	5	N/A
9/30/2020	92	-54	-9	-7	N/A
6/30/2020	85	-63	-8	-5	N/A
3/31/2020	78	-76	-154	-151	N/A
12/31/2019	27	-133	-144	-140	N/A
9/30/2019	61	-99	-144	-140	N/A
6/30/2019	62	-99	-126	-122	N/A
3/31/2019	75	-83	-105	-100	N/A
12/31/2018	60	-85	-79	-76	N/A
9/30/2018	75	-52	-28	-25	N/A
6/30/2018	87	-39	-27	-25	N/A
3/31/2018	74	-50	N/A	175	N/A
12/31/2017	72	-43	N/A	170	N/A
9/30/2017	51	-58	N/A	150	N/A
6/30/2017	30	-62	N/A	142	N/A
3/31/2017	24	-51	N/A	-16	N/A
12/31/2016	15	-59	N/A	-2	N/A
9/30/2016	11	-57	N/A	-12	N/A
6/30/2016	9	-57	N/A	-6	N/A
3/31/2016	8	-50	N/A	-28	N/A
12/31/2015	8	-42	N/A	-27	N/A
9/30/2015	8	-36	N/A	-24	N/A
6/30/2015	8	-26	N/A	30	N/A
3/31/2015	6	-24	N/A	31	N/A
12/31/2014	5	-35	N/A	32	N/A
12/31/2013	1	-19	N/A	-8	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CTMX şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -27.9% ).

Kazançlar ve Piyasa: CTMX şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -27.9% ).

Yüksek Büyüme Kazançları: CTMX şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor.

Gelir ve Pazar: CTMX şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi bekleniyor (yılda -15.2% ).

Yüksek Büyüme Geliri: CTMX şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -15.2% ).

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CTMX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

CytomX Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates upgraded to US$0.29 loss

Consensus EPS estimates fall by 138%

Consensus EPS estimates fall by 35%

Consensus EPS estimates fall by 29%

Price target increased by 47% to US$4.00

Consensus estimates of losses per share improve by 43%

Recent updates

Investor sentiment improves as stock rises 17%

Consensus EPS estimates upgraded to US$0.29 loss

Consensus EPS estimates fall by 138%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 16%

New minor risk - Market cap size

CytomX Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 35%

Investor sentiment deteriorates as stock falls 53%

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

Consensus EPS estimates fall by 29%

Price target increased by 47% to US$4.00

CytomX Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors

CytomX Therapeutics, Inc., Annual General Meeting, May 15, 2024

Chairman & CEO exercised options to buy US$239k worth of stock.

Consensus estimates of losses per share improve by 43%

CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors

Consensus revenue estimates increase by 12%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Price target increased by 9.6% to US$2.73

New minor risk - Market cap size

CytomX Therapeutics, Inc. Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

New minor risk - Profitability

Forecast breakeven date pushed back to 2024

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Consensus EPS estimates fall by 72%

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2023

CytomX Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CytomX Therapeutics, Inc. Presents Preclinical Profile of EpCAM-Directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

New minor risk - Market cap size

CytomX Therapeutics, Inc. announced that it has received $30 million in funding

Consensus revenue estimates increase by 18%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CytomX Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

CytomX Therapeutics, Inc. Appoints Yu-Waye Chu as Chief Medical Officer

New minor risk - Market cap size

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$0.66 loss

Full year 2022 earnings: EPS and revenues miss analyst expectations

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Price target decreased to US$3.31

High number of new and inexperienced directors

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

CytomX Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CytomX Therapeutics, Inc. Announces Executive Changes

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

CytomX Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Cytomx Therapeutics, Inc. to Terminate Carlos Campoy as Chief Financial Officer, Effective as of September 30, 2022

CytomX Therapeutics to cut workforce by about 40%

CytomX Therapeutics, Inc. Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation